This response to the approvable letter will support the use of Crestor over the dose range of 10-40mg in the general population of patients with lipid disorders and is scheduled for submission during the first quarter 2003.

There are now more than 10,000 patients in on-going studies of Crestor and the company remains confident in the product's profile and commercial potential.

The company's guidance on earnings for 2002 remains unchanged.